To address these current limitations, we defined a gene signature for the BRAF V600E mutation, rationalizing that a gene signature that characterizes the BRAF‐related pathways will be more informative of the sensitivity of melanoma tumors to anticancer drugs than BRAF mutations. Here, BRAF is linked to melanoma.